HIV/AIDS

Dovato is a 2-drug regimen approved for treatment-naïve adult patients with HIV infection.

Sustained virologic response rates were high among HCV/HIV coinfected patients with early treatment discontinuation the only factor associated with lower SVR rate.

A new study confirmed that HIV infection significantly increases the risk of death for patients with hepatocellular carcinoma.

A new study finds patients who have high, real, or perceived risk of HIV are more likely to accept PrEP when they have access to it.

The FDA will decide this year whether the once-daily Merck therapies can be marketed as a switch-on drug for patients with suppressed HIV-1.

A new review shows transgender women face higher HIV rates than transgender men, but also finds a relative lack of data about transmen.

New research finds participants don’t always accurately report—or know—their HIV status when enrolling in studies.

Canadian investigators identified the role of media in both promulgating and mitigating stigma of PrEP for preventing HIV transmission.

New research finds patients face a higher risk of pneumonia if they are taking opioids. The danger is even more pronounced for patients living with HIV.

A new analysis finds racial and ethnic disparities vary significantly from state to state when it comes to sexually transmitted infection rates among men who have sex with men.

In theory, the combination of ART and PrEP would be enough to virtually eradicate HIV. In the real world, they’re falling well short.

MD Magazine's most popular stories this year ranged from new clinical insights, to physician-submitted columns, to perspectives on burnout in the workplace.

The CDC found that "provider-advised deferral" of HIV antiretroviral therapy occurring less, but that US still far from goal of universal prescribing.

Modeling depicts scenarios of PrEP averting larger number, but smaller percentage of HIV infections in black than white at-risk adolescent males.

New research confirms the apparent link between schistosomiasis and risk of HIV transmission and acquisition.

A Canadian study finds patients like using an app meant to work alongside at-home HIV tests and ensure patients are quickly linked with care.

New research finds foreign-born black women aren’t benefiting from public health advances in HIV at the same rates.

New research helps explain why young gay black men have much higher rates of HIV despite also having much lower rates of risky behavior.

This past year came with a multitude of new FDA approvals for antiretroviral therapies as well as research highlighting HIV and various comorbidities.

The ethically dubious physician says he has no regrets. Here’s why.

The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.

The risk of death among formerly incarcerated people with HIV was much lower among those who had health insurance and received case management after release.

A small study shows it’s safe to give immunotherapy to patients with HIV who also have cancer.

HIV-2 is not less life-threatening than HIV-1, according to new research. The only difference is in the timing.

New research warns that the mechanisms behind HIV latency vary significantly in the blood and the gut.